Keywords: MAP Pharma, Levadex, USA, NDA filing, Allergan, Migraine

MAP Pharma gets $20 million milestone as US FDA accepts Levadex NDA

Article | 03 August 2011

California, USA-based MAP Pharmaceuticals (Nasdaq: MAPP) says that its New Drug Application for Levadex (which contains a novel formulation of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Allergan

MAP Pharmaceuticals

Go to company listing

Related Drugs

Levadex

Go to drug listing